Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Tau is a brain protein located in neurons and develops abnormally in individuals with Alzheimer disease. New technology is convenient for measuring blood total tau concentrations and provides a unique and increased opportunity for early intervention to slow cognitive decline. To evaluate the association of physical activity and total tau concentrations with cognitive decline at baseline and over time. The Chicago Health and Aging Project is a population-based cohort study conducted in 4 Chicago communities. Data collection occurred in 3-year cycles between 1993 and 2012. Participants completed in-home interviews. Clinical evaluations, which included blood samples, were performed with a stratified random sample of 1159 participants. Statistical analyses were conducted from October 30, 2020, to May 25, 2021. Physical activity and total serum tau concentrations. Data on physical activity were obtained through self-report items, and a sum of minutes per week was calculated. Little physical activity was defined as no participation in a minimum of 4 of the items on the physical activity measure. Medium activity was defined as participating in less than 150 minutes of physical activity per week, and high activity was defined as participating in 150 minutes or more of physical activity per week. The main outcome for this study is global cognitive function, measured through a battery of cognitive tests. The study hypothesis was developed after data were collected. Of the 1159 participants in the study, 728 were women (63%), and 696 were African American (60%); the mean (SD) age was 77.4 (6.0) years, and the mean (SD) educational level was 12.6 (3.5) years. Participants with high total tau concentrations with medium physical activity had a 58% slower rate of cognitive decline (estimate, -0.028 standard deviation unit [SDU] per year [95% CI, -0.057 to 0.002 SDU per year]; difference, 0.038 SDU per year [95% CI, 0.011-0.065 SDU per year]), and those with high physical activity had a 41% slower rate of cognitive decline (estimate, -0.038 SDU per year [95% CI, -0.068 to -0.009 SDU per year]; difference, 0.027 SDU per year [95% CI, -0.002 to 0.056 SDU per year]), compared with those with little physical activity. Among participants with low total tau concentrations, medium physical activity was associated with a 2% slower rate of cognitive decline (estimate, -0.050 SDU per year [95% CI, -0.069 to -0.031 SDU per year]; difference, 0.001 SDU per year [95% CI, -0.019 to 0.021 SDU per year]), and high physical activity was associated with a 27% slower rate of cognitive decline (estimate, -0.037 SDU per year [95% CI, -0.055 to -0.019 SDU per year]; difference, 0.014 SDU per year [95% CI, -0.007 to 0.034 SDU per year]), compared with little physical activity. Individual tests of cognitive function showed similar results. This study suggests that, among participants with both high and low total tau concentrations, physical activity was associated with slower cognitive decline. Results support the potential utility of blood biomarkers in measuring the benefits associated with health behaviors and may contribute to specifying target populations or informing interventions for trials that focus on improving physical activity behavior. Future work should examine the association of total tau concentrations with other health behaviors and physical activity types.
Identifiants
pubmed: 34379124
pii: 2782979
doi: 10.1001/jamanetworkopen.2021.20398
pmc: PMC8358733
doi:
Substances chimiques
Biomarkers
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2120398Subventions
Organisme : NIA NIH HHS
ID : R01 AG051635
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG058679
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG073627
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG057532
Pays : United States
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Lancet Neurol. 2016 Jun;15(7):673-684
pubmed: 27068280
Neurology. 2015 Sep 8;85(10):898-904
pubmed: 26109713
J Intern Med. 2011 Jan;269(1):107-17
pubmed: 20831630
Nat Rev Neurosci. 2007 Sep;8(9):663-72
pubmed: 17684513
Am J Epidemiol. 1988 Nov;128(5):1084-101
pubmed: 3189282
Neurology. 2014 Nov 4;83(19):1753-60
pubmed: 25298312
Am J Prev Med. 1989 Mar-Apr;5(2):65-72
pubmed: 2730794
Exp Gerontol. 2019 Jul 1;121:91-98
pubmed: 30980923
JAMA Neurol. 2019 Oct 1;76(10):1203-1210
pubmed: 31312836
J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):789-795
pubmed: 27422439
Arch Neurol. 2005 Nov;62(11):1750-4
pubmed: 16286550
Psychol Aging. 1995 Dec;10(4):578-89
pubmed: 8749585
J Neurosci Methods. 2019 May 1;319:2-6
pubmed: 30352211
ACS Chem Neurosci. 2019 Aug 21;10(8):3479-3485
pubmed: 31145586
Res Q Exerc Sport. 2000 Jun;71 Suppl 2:1-14
pubmed: 25680007
Ann Neurol. 2010 Sep;68(3):311-8
pubmed: 20818789
J Alzheimers Dis. 2003 Oct;5(5):349-55
pubmed: 14646025
Curr Sports Med Rep. 2017 Jan/Feb;16(1):19-22
pubmed: 28067736
Neurology. 2003 Sep 23;61(6):812-6
pubmed: 14504326
Curr Alzheimer Res. 2010 Dec;7(8):656-64
pubmed: 20678074
Aging Clin Exp Res. 2020 Jun;32(6):969-984
pubmed: 32026419
Alzheimers Dement. 2021 Feb 13;:
pubmed: 33580742
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
JAMA Neurol. 2019 May 1;76(5):598-606
pubmed: 30830207
J Am Med Dir Assoc. 2008 Jul;9(6):390-405
pubmed: 18585641
Alzheimers Dement (Amst). 2018 Feb 06;10:188-195
pubmed: 29527551
Ann Neurol. 2020 Dec;88(6):1065-1076
pubmed: 32799383
JAMA Neurol. 2017 Sep 1;74(9):1073-1080
pubmed: 28692710
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248